Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Parkinson Disease Clinical Trial

Official title:

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05357612
• Other study ID #: 212028
• Status: Recruiting
• Phase: Phase 4
• Start date: January 23, 2023
• Est. completion date: August 2025

Study information

• Verified date: February 2024
• Source: Vanderbilt University Medical Center
• Contact: Jason Elenberger, MS
• Phone: 6158751257
• Email: jason.elenberger[@]vumc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18F]MH.MZ in both populations.

Description:

It is hypothesized that improvement in psychosis symptoms in patients taking pimavanserin will be associated with increased baseline receptor density (Hypothesis 1A), and increased receptor occupancy of 5HT2A receptors following pimavanserin administration (Hypothesis 1B). This will be done by measuring 5HT2A receptor density using the PET radioligand (R)-[18F]MH.MZ within predefined symptom networks for hallucinations, delusions, and sleep. A PET scan will be obtained in PD patients with psychosis at enrollment to measure baseline 5HT2A receptor density and then again after 6 weeks of pimavanserin. The change in binding between baseline and post-drug treatment window will be used to measure 5HT2A receptor occupancy. It is hypothesize that improvement in psychosis symptoms in patients taking pimavanserin will be associated with increased functional connectivity and cerebral blood flow within predefined symptom networks for hallucinations, delusions, and sleep. This will be tested by obtaining MRI scans assessing resting state functional connectivity and arterial spin labeling in PD patients with psychosis at enrollment (baseline) and then again after 6 weeks of pimavanserin. It is hypothesized that functional neuroimaging changes in response to pimavanserin will be associated with baseline 5HT2A receptor density and 5HT2A receptor occupancy after pimavanserin administration. To test this hypothesis, the differences in functional neuroimaging measures and PET 5HT2A receptor will be measured in PD psychosis patients off (at baseline) and on Pimavanserin (post-treatment window).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: August 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants
• Healthy arm - age and gender matched to patient arm
• Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.
• Study partner available for study visits

Exclusion Criteria:

• Prior stroke or other uncontrolled serious neurological or medical illness
• Contra-indication or inability to tolerate MRI scan
• Use of serotonergic medications in the last 6 weeks
• Incapable of providing independent consent.
• Pregnant or breastfeeding women
• psychosis due to a metabolic, toxic, or primary psychiatric disease
• Deemed unable to complete neurocognitive testing
• For PD Participants: current or prior use of pimavanserin
• Use of antipsychotics in the last 2 weeks

Related Conditions & MeSH terms

• Neurodegenerative Diseases
• Parkinson Disease
• Parkinson Disease Psychosis

Intervention

Drug:
• Pimavanserin
PD related Psychosis

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center	ACADIA Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in 5HT2A receptor density measured using the PET radioligand MH.MZ	Receptor density (Bmax) of 5HT2A receptors measured using the PET radioligand MH.MZ uptake in regions of interest.	Baseline and 6 weeks after intervention of Pimavanserin
Primary	Change in 5HT2A receptor binding occupancy measured using the PET radioligand MH.MZ	Receptor binding occupancy (RO) of 5HT2A receptors measured using the PET radioligand MH.MZ uptake in regions of interest.	Baseline and 6 weeks after intervention of Pimavanserin
Secondary	Change in psychosis severity	Change in psychosis severity 6 weeks after starting pimavanserin, as measured by Clinician-Rated Dimensions of Psychosis Symptom Severity (CRD-PSS)18; Domain I (Delusions). Low scores indicate better outcome.	Baseline and 6 weeks after intervention of Pimavanserin
Secondary	Change in psychosis severity	Change in psychosis severity 6 weeks after starting pimavanserin, as measured by Clinician-Rated Dimensions of Psychosis Symptom Severity (CRD-PSS)18; Domain II (Hallucinations). Low scores indicate better outcome.	Baseline and 6 weeks after intervention of Pimavanserin
Secondary	Changes to functional connectivity and ASL bloodflow	Changes to functional connectivity and ASL bloodflow (mL/g/min) within pre-defined networks for delusions, hallucinations, and sleep after 6 weeks of Pimavanserin.	Baseline and 6 weeks after intervention of Pimavanserin